cost of treatment

  •   George Lundberg, MD

    As outlined in this press release on PR Newswire, it is now possible to buy many expensive drugs at very inexpensive prices from a new online pharmacy.

    .

  •  

    Encouraging and Paying for Clinical Trials, Right to Try, and Expanded Access: Part Three

    With: Mark Shapiro, PhD

    A Q&A with Mark Shapiro, PhD,Vice President of Clinical Development at xCures, Inc., Partner at Pharma Initiatives; mshapiro@xcures.com. This is the final installment in a three-part series in which Dr. Shapiro has shared his thoughts on the question below. Read part 1 and part 2. Q: Treatment of Americans with advanced cancer is complex and challenging and can be very expensive. Many urge greater participation of such patients… Read more »

  •  

    Encouraging and Paying for Clinical Trials, Right to Try, and Expanded Access: Part Two

    With: Mark Shapiro, PhD

    A Q&A with Mark Shapiro, PhD,Vice President of Clinical Development at xCures, Inc., Partner at Pharma Initiatives; mshapiro@xcures.com. Last week, Dr. Shapiro shared his initial thoughts on the question below. Today, he discusses issues of cost and equitable access to care. Q: Treatment of Americans with advanced cancer is complex and challenging and can be very expensive. Many urge greater participation of such patients in clinical trials. In… Read more »

  •  

    Encouraging and Paying for Clinical Trials, Right to Try, and Expanded Access: Part One

    With: Mark Shapiro, PhD

    A Q&A with Mark Shapiro, PhD, Vice President of Clinical Development at xCures, Inc., Partner at Pharma Initiatives; mshapiro@xcures.com Q: Treatment of Americans with advanced cancer is complex and challenging and can be very expensive. Many urge greater participation of such patients in clinical trials. In general, who pays the expenses of clinical trials? And, specifically, how are the costs for Right to Try and expanded-access approaches… Read more »

  •  

    Challenging Oncology Therapies With Moonshot Price Tags

    With: Pramod John, PhD

    A Q&A with Pramod John, PhD, CEO of VIVIO Health, a specialty drug management company in San Leandro, CA, that aims to provide better outcomes at lower costs; pramod@viviohealth.com Originally published December 13, 2017 Q: Some American pharmaceutical companies are well-known for pricing drugs at “whatever the market will bear.” In oncology, some specialty drugs seem to have price tags completely unrelated to the… Read more »